Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 8.44
(1.56%)
SEK 8.44
(1.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -310.94 Million SEK | -7.81% |
| 2022 | -288.42 Million SEK | 2.72% |
| 2021 | -296.48 Million SEK | -101.88% |
| 2020 | -146.86 Million SEK | -57.77% |
| 2019 | -93.08 Million SEK | -329.33% |
| 2018 | -21.68 Million SEK | -68.66% |
| 2017 | -12.85 Million SEK | -93.25% |
| 2016 | -6.65 Million SEK | -45.56% |
| 2015 | -4.57 Million SEK | -133.39% |
| 2014 | 13.68 Million SEK | 953.84% |
| 2013 | -1.6 Million SEK | -50659.97% |
| 2012 | -3158.00 SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 31.71 Million SEK | 128.34% |
| 2024 Q2 | -56.32 Million SEK | -277.6% |
| 2023 Q4 | -111.89 Million SEK | -76.03% |
| 2023 Q1 | -66.28 Million SEK | -9.2% |
| 2023 Q2 | -69.2 Million SEK | -4.4% |
| 2023 FY | -310.94 Million SEK | -7.81% |
| 2023 Q3 | -63.56 Million SEK | 8.15% |
| 2022 Q1 | -93.37 Million SEK | -16.16% |
| 2022 Q2 | -65.86 Million SEK | 29.46% |
| 2022 FY | -288.42 Million SEK | 2.72% |
| 2022 Q3 | -68.47 Million SEK | -3.96% |
| 2022 Q4 | -60.7 Million SEK | 11.36% |
| 2021 Q1 | -48.1 Million SEK | 17.44% |
| 2021 Q4 | -80.38 Million SEK | 17.6% |
| 2021 Q3 | -97.55 Million SEK | -38.49% |
| 2021 Q2 | -70.43 Million SEK | -46.42% |
| 2021 FY | -296.48 Million SEK | -101.88% |
| 2020 FY | -146.86 Million SEK | -57.77% |
| 2020 Q1 | -28.37 Million SEK | -2.89% |
| 2020 Q3 | -35.99 Million SEK | -48.6% |
| 2020 Q4 | -58.27 Million SEK | -61.89% |
| 2020 Q2 | -24.22 Million SEK | 14.63% |
| 2019 FY | -93.08 Million SEK | -329.33% |
| 2019 Q4 | -27.57 Million SEK | -20.46% |
| 2019 Q3 | -22.89 Million SEK | 13.83% |
| 2019 Q2 | -26.56 Million SEK | -65.6% |
| 2019 Q1 | -16.04 Million SEK | 34.21% |
| 2018 Q4 | -24.38 Million SEK | -265.77% |
| 2018 Q3 | -6.66 Million SEK | -230.34% |
| 2018 Q1 | 4.25 Million SEK | 167.77% |
| 2018 FY | -21.68 Million SEK | -68.66% |
| 2018 Q2 | 5.11 Million SEK | 20.16% |
| 2017 FY | -12.85 Million SEK | -93.25% |
| 2017 Q4 | -6.28 Million SEK | -272.38% |
| 2017 Q3 | -1.68 Million SEK | 26.68% |
| 2017 Q2 | -2.3 Million SEK | 8.47% |
| 2017 Q1 | -2.51 Million SEK | -39.51% |
| 2016 Q1 | -1.92 Million SEK | -39.1% |
| 2016 FY | -6.65 Million SEK | -45.56% |
| 2016 Q3 | -1.58 Million SEK | -18.42% |
| 2016 Q2 | -1.34 Million SEK | 30.19% |
| 2016 Q4 | -1.8 Million SEK | -13.48% |
| 2015 Q1 | -1.13 Million SEK | -110.85% |
| 2015 FY | -4.57 Million SEK | -133.39% |
| 2015 Q2 | -1.1 Million SEK | 2.91% |
| 2015 Q4 | -1.38 Million SEK | -45.06% |
| 2015 Q3 | -952 Thousand SEK | 13.61% |
| 2014 Q4 | 10.46 Million SEK | 628.48% |
| 2014 Q3 | 1.43 Million SEK | 60.45% |
| 2014 FY | 13.68 Million SEK | 953.84% |
| 2014 Q2 | 895 Thousand SEK | 0.0% |
| 2014 Q1 | 895 Thousand SEK | 169.01% |
| 2013 Q1 | 207.00 SEK | 114.7% |
| 2013 Q3 | -661 Thousand SEK | -419.32% |
| 2013 Q4 | -1.29 Million SEK | -96.22% |
| 2013 FY | -1.6 Million SEK | -50659.97% |
| 2013 Q2 | 207 Thousand SEK | 99900.0% |
| 2012 Q3 | -679.00 SEK | 0.0% |
| 2012 Q4 | -1408.00 SEK | -107.36% |
| 2012 FY | -3158.00 SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | -578.913% |
| Biovica International AB (publ) | -124.82 Million SEK | -149.106% |
| Cantargia AB (publ) | -280.02 Million SEK | -11.04% |
| CombiGene AB (publ) | -35.66 Million SEK | -771.831% |
| Cyxone AB (publ) | -22.98 Million SEK | -1252.569% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -2562.631% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1796.222% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -240.195% |
| Fluicell AB (publ) | -26.55 Million SEK | -1070.98% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -152.659% |
| Mendus AB (publ) | -101.61 Million SEK | -205.988% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -738.774% |
| I-Tech AB | 20.2 Million SEK | 1639.088% |
| Intervacc AB (publ) | -102.85 Million SEK | -202.32% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -2463.836% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 2655.198% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1637.397% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1855.364% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -70891.324% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 19.896% |
| Lipum AB (publ) | -37.17 Million SEK | -736.36% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -25.084% |
| Ziccum AB (publ) | -21.41 Million SEK | -1352.186% |
| BioArctic AB (publ) | 229.24 Million SEK | 235.635% |
| Genovis AB (publ.) | 61.5 Million SEK | 605.597% |
| Camurus AB (publ) | 431.44 Million SEK | 172.07% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -74.845% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -447.231% |
| Aptahem AB (publ) | -11.11 Million SEK | -2698.035% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -73.066% |
| Kancera AB (publ) | -64.88 Million SEK | -379.191% |
| Saniona AB (publ) | -95.81 Million SEK | -224.54% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -636.428% |
| AcouSort AB (publ) | -17.08 Million SEK | -1719.545% |
| Xintela AB (publ) | -54.08 Million SEK | -474.935% |
| Abliva AB (publ) | -95.5 Million SEK | -225.563% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 5873.153% |
| Amniotics AB (publ) | -30.87 Million SEK | -907.263% |
| 2cureX AB (publ) | -32.51 Million SEK | -856.215% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -2323.932% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 33.301% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 62.615% |
| Biosergen AB | -27.03 Million SEK | -1050.061% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1781.874% |
| Corline Biomedical AB | -1.8 Million SEK | -17088.612% |
| NextCell Pharma AB | -41.95 Million SEK | -641.047% |
| Nanologica AB (publ) | -75.15 Million SEK | -313.723% |
| LIDDS AB (publ) | -40.2 Million SEK | -673.372% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 4.882% |
| BioInvent International AB (publ) | -330.3 Million SEK | 5.862% |
| SynAct Pharma AB | -215.81 Million SEK | -44.081% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -605.82% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -1209.947% |
| Alzinova AB (publ) | -16.48 Million SEK | -1786.784% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -184.516% |
| Oncopeptides AB (publ) | -249.11 Million SEK | -24.821% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -3031.337% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -174.386% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1374.288% |
| Simris Alg AB (publ) | -37.3 Million SEK | -733.513% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -104.769% |